Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers
Authors:
- 12 October 2009
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 36 (5) , 508-517
Abstract
Objective: The aim of this study was to design bufadienolides-loaded nanostructured lipid carriers (BU-NLCs) to reduce the degradation of drugs in rat plasma. Methods: BU-NLCs were prepared by a modified melt-emulsification ultrasonic technique and then characterized by particle size distribution, zeta potential, entrapment efficiency, differential scanning calorimetry, and X-ray diffraction. Results: The optimal formulation consisted of glyceryl monostearate 1.8%, medium-chain triglyceride 0.75%, oleic acid 0.45%, Lipoid E-80® 1.5%, Pluronic F68 1.0%, and sodium deoxycholate 0.25%. The particle size distribution and the range of zeta potential of BU-NLCs were 104.1 ± 51.2 nm and −15 to −20 mV, respectively. The entrapment efficiencies of the bufadienolides were all above 85%. In the enzymolysis study, the chemical stability of cinobufagin (C) in BU-NLCs was enhanced by being encapsulated in particles of NLC and adjusting the pH of the surrounding environment to 7.0. The half-life of C was 17-fold longer than that in bufadienolides solution. The in vitro release showed that the release from BU-NLCs was slower than from bufadienolides solution and followed the Weibull equation. Differential scanning calorimetry and X-ray diffraction showed that BU-NLC was in an amorphous state after lyophilization. Conclusion: These results indicated that NLC could be developed as a carrier with improved drug plasma stability and offering controlled drug release.Keywords
This publication has 28 references indexed in Scilit:
- Preparation and evaluation of lyophilized liposome-encapsulated bufadienolidesDrug Development and Industrial Pharmacy, 2009
- Nanostructured lipid carriers (NLC) in cosmetic dermal products☆Advanced Drug Delivery Reviews, 2007
- Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cellsThe Prostate, 2002
- QSAR Evaluation of the Ch'an Su and Related Bufadienolides against the Colchicine-Resistant Primary Liver Carcinoma Cell Line PLC/PRF/5Journal of Medicinal Chemistry, 2002
- Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdvanced Drug Delivery Reviews, 2002
- Nanostructured lipid matrices for improved microencapsulation of drugsInternational Journal of Pharmaceutics, 2002
- Bufadienolides from animal and plant sourcesPhytochemistry, 1998
- Bufadienolides of plant and animal originNatural Product Reports, 1998
- Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugsLeukemia Research, 1997
- Pharmacology and toxicology of toad venomJournal of Pharmaceutical Sciences, 1967